Categories: News

Pierre Fabre Laboratories is exploring the potential of Artificial Intelligence to launch a new generation of clinical studies in dermo-cosmetics

From 100 to 600 patients: to support patients suffering from acne, Avène, Pierre Fabre Laboratories’ leading brand, is strengthening the robustness of its clinical studies via data augmentation through Artificial Intelligence.

- Advertisement -

TOULOUSE, France, March 11, 2026 /PRNewswire/ — Avène, the leading brand in French pharmacies*, in partnership with Toulouse-based HealthTech company BotDesign, has announced a major breakthrough in the field of clinical studies in dermo-cosmetics.

- Advertisement -

In 2026, Avène will conduct a comparative clinical study to evaluate the efficacy of its new treatment for acne-prone skin, Avène Cleanance Comedomed+, in the maintenance phase following oral isotretinoin treatment in adults suffering from severe to very severe acne.

- Advertisement -

Avène is renowned for its dermatological expertise, inspired by therapeutic know-how, and has been committed to improving the treatment of skin pathologies since 1990. It is thus becoming the first brand to use Artificial Intelligence in clinical studies for dermo-cosmetics.

- Advertisement -

A concrete illustration of Pierre Fabre Laboratories’ “Supportive Care” strategy.

- Advertisement -

This study is unique in two ways: due to its scientific ambition and because it fully aligns with the “supportive care” strategy of Pierre Fabre Laboratories, launched in 2025.

- Advertisement -

“We belong to a group that has always been rooted in pharmaceuticals and dermo-cosmetics. Our medical expertise gives us a head start in understanding patients and their pathologies. We are ideally positioned to offer treatment protocols based on the pathology, combining dermo-cosmetics with medication. We are already preparing solutions to go further, by developing dermo-cosmetic innovations capable of extending and amplifying the action of the medication or delaying its necessity. Because these are dermo-cosmetics, they can be used over the long term, unlike many drug treatments,” explains Dr. Gautier Doat, Eau Thermale Avène Medical Director.

- Advertisement -

To continue reading, https://www.pierre-fabre.com/en/news/avene-artificial-intelligence-clinical-studies-dermo-cosmetics

- Advertisement -

For more information, visit www.pierre-fabre.com,  @Laboratoires Pierre Fabre@Pierre Fabre Oncology

- Advertisement -

About Eau Thermale Avènehttps://www.eau-thermale-avene.fr/

- Advertisement -

Press contact: Caroline Perdrix Thomas 
caroline.perdrix@pierre-fabre.com

- Advertisement -

*Source: GERS – SOG Early – Pharmacy Channel – Dermo-cosmetics market definition established by Pierre Fabre laboratories – Origin: Sell Out – Cumulative data up to December 2025 in volume (units) and value (revenue inc. taxes). 

- Advertisement -

Photo – https://mma.prnewswire.com/media/2930570/Avene_Cleanance.jpg
Logo – https://mma.prnewswire.com/media/2930569/PIERRE_FABRE_Avene_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/pierre-fabre-laboratories-is-exploring-the-potential-of-artificial-intelligence-to-launch-a-new-generation-of-clinical-studies-in-dermo-cosmetics-302711198.html

- Advertisement -

Recent Posts

LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimers Disease Presented at the Alzheimers Association International Conference (AAIC) 2026

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment,…

50 minutes ago

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

The new data demonstrates the potential to improve control of acute infection, latency, and viral…

50 minutes ago

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

July 12, 2026 06:28 ET  | Source: Hemab Therapeutics, Inc. HMB-002 clinical data demonstrate proof…

50 minutes ago

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2026

FORMER ELITE SOCCER PLAYERS SHOWEVIDENCE OF BRAIN HEALTH CHANGES IN MID-LIFEKey TakeawaysNew research provides insights…

51 minutes ago

GAC Group to Celebrate 30 Million Global Users on July 16

GUANGZHOU, China, July 12, 2026 /PRNewswire/ -- From the roll-off of its first vehicle to…

4 hours ago

What Separates Commercial Money Counters From Consumer Models?

MIAMI, FL, July 11, 2026 (GLOBE NEWSWIRE) -- To a first-time buyer, a consumer money…

14 hours ago